Get the latest news alerts: at Twitter.

Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Biotechnology firm is expanding its management team with a vice president for business development post.

Thomas Pilter, a 25-year business veteran, is taking on the new role.

Chimerix revamped its management team earlier in the week, naming a new chief executive officer and shuffling its board of directors.

Kenneth Moch was promoted to CEO and also to the board. Pitler will report to him.

"Tom brings to Chimerix the notable combination of industry deal-making with operations and research experience," Moch said in a statement. "Tom is uniquely qualified to expand Chimerix’s strategic alliances and opportunities to develop significant value from Chimerix’s extraordinary pipeline of therapeutics against a range of challenging viral diseases. We look forward to working with him."

Moch had been the chief operating officer. He replaces George Painter, who is now the firm’s chief scientific officer. Painter also is the company’s board chairman.

The changes were announced Tuesday.

Chimerix is developing antiviral therapeutics that can be delivered orally.

Pilter most recently worked as chief business and financial officer at Neurogen, which recently was acquired by Ligand Pharmaceuticals. Pilter had worked for Neurogen since 1995, beginning as a scientist in research and development. He earned a PhD in physiology and an undergraduate degree in biology at Wake Forest University.